• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在城市层面上能否实现 COVID-19 群体免疫?

Can COVID-19 herd immunity be achieved at a city level?

机构信息

Sir Harry Solomon School of Economics and Management, Western Galilee College, Acre, Israel.

Department of Mathematics, Bar Ilan University, Ramat Gan, Israel.

出版信息

PLoS One. 2024 May 29;19(5):e0299574. doi: 10.1371/journal.pone.0299574. eCollection 2024.

DOI:10.1371/journal.pone.0299574
PMID:38809902
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11135690/
Abstract

We propose a new approach to estimate the vaccination rates required to achieve herd immunity against SARS-COV2 virus at a city level. Based on information obtained from the Israeli Ministry of Health, we estimate two separate quadratic models, one for each dose of the BNT162b2 mRNA Pfizer vaccine. The dependent variable is the scope of morbidity, expressed as the number of cases per 10,000 persons. The independent variables are the first and second vaccination rates and their squares. The outcomes corroborate that herd immunity is achieved in the case that 71 percent of the urban population is vaccinated, and the minimum anticipated scope of morbidity is approximately 5 active COVID-19 cases per 10,000 persons, compared to 53-67 cases per 10,000 persons for zero vaccination rate. Findings emphasize the importance of vaccinations and demonstrate that urban herd immunity may be defined as a situation in which people continue to interact, yet the COVID-19 spread is contained. This, in turn, might prevent the need for lockdowns or other limitations at the city level.

摘要

我们提出了一种新方法来估计在城市层面上达到 SARS-COV2 病毒群体免疫所需的疫苗接种率。基于从以色列卫生部获得的信息,我们估计了两种单独的二次模型,一种针对 BNT162b2 mRNA 辉瑞疫苗的第一剂,另一种针对第二剂。因变量是发病率范围,以每 10000 人中有多少病例表示。自变量是第一剂和第二剂疫苗接种率及其平方。结果证实,如果城市人口中有 71%的人接种了疫苗,那么就可以实现群体免疫,预计最低发病率范围约为每 10000 人中有 5 例活动性 COVID-19 病例,而零接种率的发病率范围为每 10000 人中有 53-67 例。这些发现强调了疫苗接种的重要性,并表明城市群体免疫可以定义为人们继续互动,但 COVID-19 传播得到控制的情况。这反过来又可能防止城市层面需要封锁或其他限制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d96b/11135690/4c679280a286/pone.0299574.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d96b/11135690/24149e1a37cb/pone.0299574.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d96b/11135690/44c87631b77c/pone.0299574.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d96b/11135690/3858bc956f20/pone.0299574.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d96b/11135690/2daafc014ecb/pone.0299574.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d96b/11135690/4c679280a286/pone.0299574.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d96b/11135690/24149e1a37cb/pone.0299574.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d96b/11135690/44c87631b77c/pone.0299574.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d96b/11135690/3858bc956f20/pone.0299574.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d96b/11135690/2daafc014ecb/pone.0299574.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d96b/11135690/4c679280a286/pone.0299574.g005.jpg

相似文献

1
Can COVID-19 herd immunity be achieved at a city level?在城市层面上能否实现 COVID-19 群体免疫?
PLoS One. 2024 May 29;19(5):e0299574. doi: 10.1371/journal.pone.0299574. eCollection 2024.
2
Modelling direct and herd protection effects of vaccination against the SARS-CoV-2 Delta variant in Australia.建模澳大利亚针对 SARS-CoV-2 Delta 变异株的疫苗接种对直接和群体保护的效果。
Med J Aust. 2021 Nov 1;215(9):427-432. doi: 10.5694/mja2.51263. Epub 2021 Oct 11.
3
Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.智利科兴和国药疫苗接种后动态 IgG 血清阳性率:哨点监测研究。
Lancet Infect Dis. 2022 Jan;22(1):56-63. doi: 10.1016/S1473-3099(21)00479-5. Epub 2021 Sep 9.
4
Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.以色列卫生保健工作者中,第三剂 BNT162b2 疫苗接种与 SARS-CoV-2 感染发生率的关联。
JAMA. 2022 Jan 25;327(4):341-349. doi: 10.1001/jama.2021.23641.
5
Waning Immunity after the BNT162b2 Vaccine in Israel.以色列接种 BNT162b2 疫苗后的免疫力下降。
N Engl J Med. 2021 Dec 9;385(24):e85. doi: 10.1056/NEJMoa2114228. Epub 2021 Oct 27.
6
Model based estimation of the SARS-CoV-2 immunization level in austria and consequences for herd immunity effects.基于模型的奥地利 SARS-CoV-2 免疫水平估计及其对群体免疫效果的影响。
Sci Rep. 2022 Feb 21;12(1):2872. doi: 10.1038/s41598-022-06771-x.
7
Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.基于 SARS-CoV-2 的免疫原性结构蛋白、宿主免疫反应和群体免疫的 COVID-19 疫苗开发的新见解。
Cells. 2021 Oct 29;10(11):2949. doi: 10.3390/cells10112949.
8
BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.BNT162b2 新冠病毒疫苗与体液免疫应答及动力学的相关性:医护人员前瞻性、单中心、纵向队列研究。
Lancet Respir Med. 2021 Sep;9(9):999-1009. doi: 10.1016/S2213-2600(21)00220-4. Epub 2021 Jul 2.
9
Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.辉瑞/生物科技和牛津/阿斯利康疫苗对沙特阿拉伯全国疫苗接种运动中真实环境下 COVID-19 发病率和死亡率的影响。
Eur Rev Med Pharmacol Sci. 2021 Nov;25(22):7185-7191. doi: 10.26355/eurrev_202111_27271.
10
Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2.保护和衰减对 SARS-CoV-2 的天然和混合免疫。
N Engl J Med. 2022 Jun 9;386(23):2201-2212. doi: 10.1056/NEJMoa2118946. Epub 2022 May 25.

引用本文的文献

1
Melanoma prevalence: can medical literacy overcome the rise in UV radiation? United States as a case study.黑色素瘤患病率:医学素养能否遏制紫外线辐射增加的趋势?以美国为例进行研究
Front Public Health. 2025 Aug 6;13:1636571. doi: 10.3389/fpubh.2025.1636571. eCollection 2025.
2
Development of a data-driven urban immunity assessment model: providing a new benchmark for urban governance under public health emergencies.数据驱动的城市免疫力评估模型的开发:为突发公共卫生事件下的城市治理提供新基准
Front Public Health. 2025 May 29;13:1609641. doi: 10.3389/fpubh.2025.1609641. eCollection 2025.

本文引用的文献

1
Baseline clinical features of COVID-19 patients, delay of hospital admission and clinical outcome: A complex relationship.COVID-19 患者的基线临床特征、住院延迟与临床结局:复杂的关系。
PLoS One. 2022 Jan 7;17(1):e0261428. doi: 10.1371/journal.pone.0261428. eCollection 2022.
2
Burden and characteristics of COVID-19 in the United States during 2020.2020 年美国 COVID-19 的负担和特征。
Nature. 2021 Oct;598(7880):338-341. doi: 10.1038/s41586-021-03914-4. Epub 2021 Aug 26.
3
Undiagnosed SARS-CoV-2 seropositivity during the first 6 months of the COVID-19 pandemic in the United States.
美国新冠疫情头6个月期间未确诊的新冠病毒血清阳性情况。
Sci Transl Med. 2021 Jul 7;13(601). doi: 10.1126/scitranslmed.abh3826. Epub 2021 Jun 22.
4
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.BNT162b2 mRNA 新冠病毒疫苗在全国大规模疫苗接种环境中的效果。
N Engl J Med. 2021 Apr 15;384(15):1412-1423. doi: 10.1056/NEJMoa2101765. Epub 2021 Feb 24.
5
On the emergence of a power law in the distribution of COVID-19 cases.关于新冠病毒疾病病例分布中幂律的出现。
Physica D. 2020 Nov;412:132649. doi: 10.1016/j.physd.2020.132649. Epub 2020 Jul 16.
6
Dynamics of Population Immunity Due to the Herd Effect in the COVID-19 Pandemic.新冠疫情中群体效应导致的人群免疫动态
Vaccines (Basel). 2020 May 19;8(2):236. doi: 10.3390/vaccines8020236.